Targeted therapy directed by genetic testing in treating patients with advanced solid tumors, lymphomas, or multiple myeloma
Will identifying genetic abnormalities in tumor cells help doctors plan better, more personalized treatment for cancer patients?
a study on Malignant Solid Neoplasm Bladder Cancer Breast Cancer Cervical Cancer Colon Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer Stomach Cancer Glioma Head and Neck Cancer Kidney Cancer Cholangiocarcinoma Lung Cancer Lymphoma Malignant Uterine Neoplasm Melanoma Skin Cancer/Melanoma Ovarian Cancer Pancreatic Cancer Multiple Myeloma Prostate Cancer Rectal Cancer Liver Cancer Thyroid Gland Carcinoma Uterine Cancer Refractory Malignant Solid Neoplasm Solid Tumor
Advanced Malignant Solid Neoplasm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Cancer Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer Carcinoma Neoplasms Multiple Myeloma Neoplasms, Plasma Cell Breast Neoplasms Lung Neoplasms Colorectal Neoplasms Endometrial Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Prostatic Neoplasms Pancreatic Neoplasms Esophageal Neoplasms Stomach Neoplasms Urinary Bladder Neoplasms Rectal Neoplasms Thyroid Neoplasms Uterine Neoplasms Colonic Neoplasms Carcinoma, Hepatocellular Skin Neoplasms Carcinoma, Renal Cell Kidney Neoplasms Thyroid Diseases Antineoplastic Agents, Immunological Nivolumab Trastuzumab Pertuzumab Ado-Trastuzumab Emtansine Sunitinib Dasatinib Palbociclib Trametinib Afatinib Osimertinib Dabrafenib Crizotinib Maytansine Trastuzumab biosimilar HLX02 GSK2636771 Antibodies Immunoglobulins Antibodies, Monoclonal Immunoglobulin G Immunoconjugates Adavosertib Afatinib Dimaleate Binimetinib Capivasertib Copanlisib Copanlisib Hydrochloride Cytology Specimen Collection Procedure Dabrafenib Mesylate Defactinib Defactinib Hydrochloride Erdafitinib FGFR Inhibitor AZD4547 Ipatasertib Laboratory Biomarker Analysis Larotrectinib Larotrectinib Sulfate PI3K-beta Inhibitor GSK2636771 Relatlimab Sapanisertib Sunitinib Malate Taselisib Trastuzumab Emtansine Ulixertinib Vismodegib
Lead Scientists at UC Cancer
- Daniela A. Bota (uci)
Professor, Neurology. Authored (or co-authored) 76 research publications.
- Shumei Kato (ucsd)
Associate Clinical Professor, Medicine. Authored (or co-authored) 83 research publications.
- Primo N. Lara (ucdavis)
Professor, Hematology and Oncology. Authored (or co-authored) 286 research publications.
- accepting new patients
- Start Date
- Completion Date
- National Cancer Institute (NCI)
- Phase 2
- Study Type
- Last Updated